Food and Drug Administration as an adjunct in the management of patients with benzodiazepine toxicity. The presence or absence of a clinical response to a benzodiazepine antagonist can also provide diagnostic information, analogous to the specific reversal of the effects of opiates by naloxone (Narcan).įlumazenil (Mazicon) has been approved by the U.S. Selective pharmacologic reversal of these effects may obviate the need for mechanical ventilation or other invasive supportive procedures. However, these agents can cause respiratory and central nervous system depression, which may lead to hypoventilation or aspiration of gastric contents. Serious toxicity seldom occurs with benzodiazepines. In addition, these drugs are often implicated in intentional or iatrogenic overdose. Because of their sedative and amnestic properties, benzodiazepines are also used in patients who are undergoing anesthesia. These agents are widely used in the management of insomnia, seizure disorders, and panic and anxiety states. ![]() It was introduced in 1987 by Hoffmann-La Roche under trade name Anexate.įlumazenil: an antidote for benzodiazepine toxicity - Clinical Pharmacologyīenzodiazepines are the most commonly prescribed sedative-hypnotic drugs in the United States. Therefore repeat doses of flumazenil may be required to prevent recurrent symptoms of overdosage once the initial dose of flumazenil wears off. Many benzodiazepines have longer half-lives than flumazenil. The onset of action is very fast, about one to two minutes. It reverses the effects of benzodiazepines by competitive inhibition of benzodiazepine receptors. Flumazenil: Flumazenil: an antidote for benzodiazepine toxicity - Clinical Pharmacology at The Medical Dictionaryįind information on thousands of medical conditions and prescription drugs.įlumazenil (flumazepil,, Ro 15-1788, Anexate®, Lanexat®, Mazicon®, Romazicon®) is a benzodiazepine antagonist, used as an antidote in the treatment of benzodiazepine overdose.
0 Comments
Leave a Reply. |